Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Analytical and forensic aspects of counterfeit peptide hormones

Carvalho M, Dinis-Oliveira RJ. Drug Testing and Analysis 2023

Document identifier
CEI-BR-009
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Carvalho M, Dinis-Oliveira RJ
Title
Analytical and forensic aspects of counterfeit peptide hormones
Source
Drug Testing and Analysis
Year
2023
Volume, issue, pages
15(1):5–19
Digital object identifier
not held by the Institute
PubMed identifier
not held by the Institute
Record type
Journal article
Institute identifier
CEI-BR-009

Institute note. The digital object identifier previously carried on this record did not resolve and has been withdrawn. Journal and year are retained.

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: AOD-9604Compound monograph
Monograph: BPC-157Compound monograph
Monograph: Melanotan-IICompound monograph
Synthesis: Analytical surveys of unregulated peptide supplyEvidence synthesis
4 citing documents.

§1.3Subject tags

counterfeit forensic analytical

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.